[1] Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
[2] Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol. 2000;32(1):78-84.
[3] Cartwright P, McLean C, Sheppard A, et al. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development. 2005;132(5): 885-896.
[4] Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976-990.
[5] Polo JM, Anderssen E, Walsh RM, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell. 2012; 151(7):1617-1632.
[6] 张登才,刘斌,张丽华,等.一种简便实用的组织芯片制作方法[J]. 诊断病理学杂志,2013,20(11):722-724.
[7] 王宁,孙婷婷, 郑荣寿, 等.中国2009年结直肠癌发病和死亡资料分析[J].中国肿瘤,2013,22(7): 515-520.
[8] 武鸣,张思维,韩仁强.2004-2005 年中国结直肠和肛门癌死亡水平分析[J].中华预防医学杂志,2010,44(5):403-407.
[9] Hohenberger W, Weber K, Matzel K, et al. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis. 2009;11(4):354-364.
[10] Baek SK, Carmichael JC, Pigazzi A. Robotic surgery: colon and rectum.Cancer J. 2013;19(2):140-146.
[11] de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16): 2938-2947.
[12] Díaz-Rubio E, Tabernero J, Gómez-España A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial .J Clin Oncol. 2007;25(27):4224-4230.
[13] Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol. 2006;24(21):3347-3353.
[14] 李宇飞,李华山.结直肠肿瘤中医药治疗的研究进展[J].世界华人消化杂志,2012,20(36):3748-3753.
[15] 刘劲松,李丽萍,刘俊.复方苦参注射液联合化疗治疗对结直肠癌患者血清血管内皮生长因子的影响[J].中国老年学杂志,2014, 34(2):333-334.
[16] 海艳洁,郑宇,庄亚严,等.槐耳颗粒联合化疗对晚期大肠癌的初步临床研究[J].药物流行病学杂志,2012,21(2):53-55.
[17] 张勇,许建华,孙珏,等.健脾解毒方联合 FOLFOX4 方案治疗晚期结直肠癌临床研究[J].环球中医药,2010,3(2):117-120.
[18] Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.
[19] Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002;3(8): 508-513.
[20] Wend P, Holland JD, Ziebold U, et al. Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol. 2010;21(8): 855-863.
[21] Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008; 14(21): 6751-6760.
[22] 王芙蓉,刘斌,苏勤军,等.结直肠癌组织中CD44+肿瘤细胞与S期标志物增殖细胞核抗原的关系[J].中国组织工程研究与临床康复, 2011, 15(40): 7537-7540.
[23] Carpentino JE, Hynes MJ, Appelman HD, et al. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 2009;69(20):8208-8215.
[24] Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-10163.
[25] 张登才,刘斌,张丽华,等.结直肠腺癌组织中CD44+/Oct4+癌干细胞的形态及分布[J].中国组织工程研究, 2013, 17(49): 8461-8467.
[26] Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008; 14(21):6751-6760.
[27] Böckelman C, Koskensalo S, Hagström J, et al. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther. 2012;13(5):289-295.
[28] 罗瑾,李燕妮,耿鑫,等. S-腺苷甲硫氨酸抑制大肠癌细胞生长的实验研究[J].生物医学工程与临床,2011,15(2): 183-186.
[29] Yu Z, Pestell TG, Lisanti MP, et al. Cancer stem cells. Int J Biochem Cell Biol. 2012;44(12):2144-2151.
[30] He S, Nakada D, Morrison SJ. Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol. 2009;25:377-406. |